Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin
dc.contributor.author | Agarwal, K | en_US |
dc.contributor.author | Schultz, M | en_US |
dc.contributor.author | Pianko, S | en_US |
dc.contributor.author | Bank, L | en_US |
dc.contributor.author | Collier, J | en_US |
dc.contributor.author | George, J | en_US |
dc.contributor.author | Priest, M | en_US |
dc.contributor.author | Ryder, SD | en_US |
dc.contributor.author | Burman, BE | en_US |
dc.contributor.author | Cheent, K | en_US |
dc.contributor.author | Cramp, M | en_US |
dc.contributor.author | Forton, DM | en_US |
dc.contributor.author | Leggett, BA | en_US |
dc.contributor.author | MacQuillan, GC | en_US |
dc.contributor.author | Ramji, A | en_US |
dc.contributor.author | Richardson, P | en_US |
dc.contributor.author | Ryan, MJ | en_US |
dc.contributor.author | Stace, N | en_US |
dc.contributor.author | Zekry, A | en_US |
dc.contributor.author | Zogg, DL | en_US |
dc.contributor.author | Barnes, E | en_US |
dc.contributor.author | Brainard, DM | en_US |
dc.contributor.author | Massetto, B | en_US |
dc.contributor.author | Chen, F | en_US |
dc.contributor.author | McHutchison, JG | en_US |
dc.contributor.author | Subramanian, M | en_US |
dc.contributor.author | Yoshida, EM | en_US |
dc.contributor.author | Foster, GR | en_US |
dc.date.accessioned | 2017-03-15T15:14:42Z | |
dc.date.issued | 2016-10 | en_US |
dc.date.submitted | 2017-01-04T08:25:29.661Z | |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/20679 | |
dc.description.sponsorship | Amer Assoc Study Liver Dis | en_US |
dc.format.extent | 455A - 456A | en_US |
dc.title | Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin | en_US |
dc.type | Conference Proceeding | |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 64 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Centre for Immunobiology [1121]